Cited by 1,381Cell Adhesion Molecules ResearchCellular Mechanics and InteractionsCancer Cells and Metastasis

The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.

FAK in cancer: mechanistic findings and clinical applications

Open access

Sulzmaier, Florian J., Jean, Christine, Schlaepfer, David D.·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. FAK promotes tumour progression and metastasis through effects on cancer cells, as well as stromal cells of the tumour microenvironment. The kinase-dependent and kinase-independent functions of FAK control cell movement, invasion, survival, gene expression and cancer stem cell self-renewal. Small molecule FAK inhibitors decrease tumour growth and metastasis in several preclinical models and have initial clinical activity in patients with limited adverse events. In this Review, we discuss FAK signalling effects on both tumour and stromal cell biology that provide rationale and support for future therapeutic opportunities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc3792

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Focal adhesion kinase: in command and control of cell motility
Mitra, S. K., Hanson, D. A., & Schlaepfer, D. D. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1549 · Cited by 2,657
Self-citation
Focal adhesion kinase: the first ten years
Parsons, J. T. (2003) · Journal of Cell Science · doi:10.1242/jcs.00373 · Cited by 1,389
The role of focal-adhesion kinase in cancer — a new therapeutic opportunity
McLean, G. W., Carragher, N. O., Avizienyte, E., EVANS, J., Brunton, V. G., & Frame, M. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1647 · Cited by 1,049
E-cadherin–integrin crosstalk in cancer invasion and metastasis
Canel, M., Serrels, A., Frame, M. C., & Brunton, V. G. (2013) · Journal of Cell Science · doi:10.1242/jcs.100115 · Cited by 651
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
Schaller, M. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.045112 · Cited by 613
Signal transduction by focal adhesion kinase in cancer
Zhao, J., & Guan, J. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9165-4 · Cited by 608

Flagged first, then by citations

Show all 142 references

Sorted by citations

Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,591
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Physical traits of cancer
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 882
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 882
FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies
Claesson, L., Dejana, E., & McDonald, D. M. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.11.006 · Cited by 657
Organization, dynamics and mechanoregulation of integrin-mediated cell–ECM adhesions
Kanchanawong, P., & Calderwood, D. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00531-5 · Cited by 630
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
FAK signaling in human cancer as a target for therapeutics
Lee, B. Y., Timpson, P., Horvath, L. G., & Daly, R. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.001 · Cited by 439
Tumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 407
Self-citation
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaïb, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 391
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 389
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & Maria, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 345
Loss of fibronectin from the aged stem cell niche affects the regenerative capacity of skeletal muscle in mice
Lukjanenko, L., Jung, M. J., Hegde, N., Perruisseau-Carrier, C., Migliavacca, E., Rozo, M., Karaz, S., Jacot, G. E., Schmidt, M., Li, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4126 · Cited by 347
Cancer cell behaviors mediated by dysregulated pH dynamics at a glance
White, K. A., Grillo‐Hill, B. K., & Barber, D. L. (2017) · Journal of Cell Science · doi:10.1242/jcs.195297 · Cited by 330
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J. G., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 320
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293
Targeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 297
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin
Theodosiou, M., Widmaier, M., Böttcher, R. T., Rognoni, E., Veelders, M., Bharadwaj, M., Lambacher, A., Austen, K., Müller, D. J., Zent, R., et al. (2016) · eLife · doi:10.7554/elife.10130 · Cited by 279
Extracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
“Changes in matrix composition or stiffness, cytokines, growth factors, integrins, and pH trigger FAK activity through the αvβ5/FAK/PI3K/Akt signaling pathway [146] to prevent anoikis and other types of cell death.”
Tetraspanins Function as Regulators of Cellular Signaling
Termini, C. M., & Gillette, J. M. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00034 · Cited by 267
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Diehl, C. J., & Ciulli, A. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00387b · Cited by 269
Current treatment options for meningioma
Apra, C., Peyre, M., & Kalamarides, M. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1429920 · Cited by 254
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Osipov, A., Saung, M. T., Zheng, L., & Murphy, A. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0667-0 · Cited by 252
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy
Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 246
A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK
Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.009 · Cited by 237
Self-citation
Advances on Natural Polyphenols as Anticancer Agents for Skin Cancer
Sajadimajd, S., Bahramsoltani, R., Iranpanah, A., Patra, J. K., Das, G., Gouda, S., Rahimi, R., Rezaeiamiri, E., Cao, H., Giampieri, F., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104584 · Cited by 238
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer
Yang, H., Li, X., Meng, Q., Sun, H., Wu, S., Hu, W., Liu, G., Li, X., Yang, Y., & Chen, R. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1139-3 · Cited by 234
Redox regulation in tumor cell epithelial–mesenchymal transition: molecular basis and therapeutic strategy
Jiang, J., Wang, K., Chen, Y., Chen, H., Nice, E. C., & Huang, C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.36 · Cited by 233
Emerging Roles of Focal Adhesion Kinase in Cancer
Tai, Y.-L., Chen, L., & Shen, T. (2015) · BioMed Research International · doi:10.1155/2015/690690 · Cited by 233
Understanding the Roles of FAK in Cancer
Yoon, H., Dehart, J. P., Murphy, J. M., & Lim, S. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414561498 · Cited by 228
Focal adhesion kinase signaling in unexpected places
Kleinschmidt, E. G., & Schlaepfer, D. D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.01.003 · Cited by 219
Self-citation
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment
Murphy, J. M., Rodriguez, Y. A. R., Jeong, K., Ahn, E.-Y. E., & Lim, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0447-4 · Cited by 226
Prognostic biomarkers in oral squamous cell carcinoma: A systematic review
Rivera, C., Oliveira, A. K., Costa, R. A. P. E., Rossi, T. D., & Leme, A. F. P. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.003 · Cited by 218
FAK Structure and Regulation by Membrane Interactions and Force in Focal Adhesions
Tapial Martínez, P., López Navajas, P., & Lietha, D. (2020) · Biomolecules · doi:10.3390/biom10020179 · Cited by 206
“The importance of FAK in cell motility is also reflected in disease where FAK plays major roles in tumour invasion and metastasis [11].”
Background
Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy
Chamcheu, J. C., Roy, T., Uddin, M. B., Banang‐Mbeumi, S., Chamcheu, R. N., Walker, A. L., Liu, Y., & Huang, S. (2019) · Cells · doi:10.3390/cells8080803 · Cited by 212
Mechanisms of Selective Autophagy in Normal Physiology and Cancer
Mancias, J. D., & Kimmelman, A. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.027 · Cited by 196
PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion
Caino, M. C., Ghosh, J. C., Chae, Y. C., Vaira, V., Rivadeneira, D. B., Faversani, A., Rampini, P. M., Kossenkov, A. V., Aird, K. M., Zhang, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500722112 · Cited by 204
Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?
Belhabib, I., Zaghdoudi, S., Lac, C., Bousquet, C., & Jean, C. (2021) · Cancers · doi:10.3390/cancers13143466 · Cited by 210
Self-citation
Autophagy and epithelial–mesenchymal transition: an intricate interplay in cancer
Gugnoni, M., Sancisi, V., Manzotti, G., Gandolfi, G., & Ciarrocchi, A. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.415 · Cited by 205
Mechanisms and context underlying the role of autophagy in cancer metastasis
Dower, C. M., Wills, C. A., Frisch, S. M., & Wang, H. (2018) · Autophagy · doi:10.1080/15548627.2018.1450020 · Cited by 196
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling
Shen, M., Jiang, Y., Wei, Y., Ell, B. J., Sheng, X., Esposito, M., Kang, J., Hang, X., Zheng, H., Rowicki, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.016 · Cited by 203
Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix
Yuzhalin, A. E., Gordon-Weeks, A. N., Tognoli, M. L., Jones, K. I., Markelc, B., Konietzny, R., Fischer, R., Muth, A., O’Neill, E. E., Thompson, P. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07306-7 · Cited by 195
Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression
Seager, R. J., Hajal, C., Spill, F., Kamm, R. D., & Zaman, M. H. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa7e86 · Cited by 192
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer
Thakur, R. K., Trivedi, R., Rastogi, N., Singh, M., & Mishra, D. P. (2015) · Scientific Reports · doi:10.1038/srep10194 · Cited by 187
FAK in Cancer: From Mechanisms to Therapeutic Strategies
Chuang, H.-H., Zhen, Y., Tsai, Y.-C., Chuang, C., Hsiao, M., Huang, M., & Yang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031726 · Cited by 193
EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation
Zhang, L., Qu, J., Qi, Y., Duan, Y., Huang, Y.-W., Zhou, Z., Li, P., Yao, J., Huang, B., Zhang, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30105-0 · Cited by 182
CXCL12/CXCR4 activation by cancer‐associated fibroblasts promotes integrin β1 clustering and invasiveness in gastric cancer
Izumi, D., Ishimoto, T., Miyake, K., Sugihara, H., Eto, K., Sawayama, H., Yasuda, T., Kiyozumi, Y., Kaida, T., Kurashige, J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29864 · Cited by 188
Matrix Stiffness: the Conductor of Organ Fibrosis
Santos, A., & Lagares, D. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0710-z · Cited by 183
ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1
Patwardhan, S., Mahadik, P., Shetty, O. A., & Sen, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121185 · Cited by 183
FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis
Lachowski, D., Cortes, E., Robinson, B., Rice, A., Rombouts, K., & Del Río Hernández, A. E. (2018) · The FASEB Journal · doi:10.1096/fj.201700721r · Cited by 175
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer
Zhang, H., Schaefer, A., Wang, Y., Hodge, R. G., Blake, D. R., Diehl, J. N., Papageorge, A. G., Stachler, M. D., Liao, J., Zhou, J. R., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0811 · Cited by 170
Recent Advances in Pyrimidine-Based Drugs
Nammalwar, B., & Bunce, R. A. (2024) · Pharmaceuticals · doi:10.3390/ph17010104 · Cited by 171
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression
Cohen-Solal, K., Boregowda, R. K., & Lasfar, A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0404-3 · Cited by 170
CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2
Wu, C. Y.-J., Chen, C., Lin, C., Feng, L.-Y., Lin, Y., Wei, K., Huang, C.-Y., Fang, J., & Chen, P. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz189 · Cited by 165
Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction
Lee, S.-J., Lee, C.-K., Kang, S., Park, I., Kim, Y. H., Kim, S. K., Hong, S. P., Bae, H., He, Y., Kubota, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99659 · Cited by 164
Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy
Domoto, T., Pyko, I. V., Furuta, T., Miyashita, K., Uehara, M., Shimasaki, T., Nakada, M., & Minamoto, T. (2016) · Cancer Science · doi:10.1111/cas.13028 · Cited by 161
Focal adhesion kinase: from biological functions to therapeutic strategies
Tan, X., Yan, Y., Song, B., Zhu, S., Mei, Q., & Wu, K. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00446-7 · Cited by 158
Cancer associated fibroblast FAK regulates malignant cell metabolism
Demircioglu, F., Wang, J., Candido, J. B., Costa, A. S. H., Casado, P., de Luxán‐Delgado, B., Reynolds, L. E., Gómez-Escudero, J., Newport, E., Rajeeve, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15104-3 · Cited by 158
Decoding leader cells in collective cancer invasion
Mercedes, S. A. V., Bocci, F., Levine, H., Onuchic, J. N., Jolly, M. K., & Wong, P. K. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00376-8 · Cited by 153
MMP proteolytic activity regulates cancer invasiveness by modulating integrins
Das, A., Monteiro, M., Barai, A., Kumar, S., & Sen, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-14340-w · Cited by 156
A Novel Phytochemical, DIM, Inhibits Proliferation, Migration, Invasion and TNF-α Induced Inflammatory Cytokine Production of Synovial Fibroblasts From Rheumatoid Arthritis Patients by Targeting MAPK and AKT/mTOR Signal Pathway
Du, H., Zhang, X., Zeng, Y., Huang, X., Chen, H., Wang, S., Wu, J., Li, Q., Zhu, W., Li, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01620 · Cited by 150
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Soria, J., Gan, H. K., Blagden, S. P., Plummer, R., Arkenau, H., Ranson, M., Evans, T. R. J., Zalcman, G., Bahleda, R., Hollebecque, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw427 · Cited by 148
Annexin A2 and cancer: A systematic review
Christensen, M., Høgdall, C. K., Jochumsen, K. M., & Høgdall, E. V. S. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4197 · Cited by 148
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Self-citation
Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis
Yuzhalin, A. E., Lim, S. Y., Kutikhin, A. G., & Gordon-Weeks, A. N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.09.002 · Cited by 147
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 146
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 144
Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01826 · Cited by 138
Complementary Alu sequences mediate enhancer–promoter selectivity
Liang, L., Cao, C., Ji, L., Cai, Z., Wang, D., Ye, R., Chen, J., Yu, X., Zhou, J., Bai, Z., et al. (2023) · Nature · doi:10.1038/s41586-023-06323-x · Cited by 147
Periodontal pathogens promote cancer aggressivity via TLR/MyD88 triggered activation of Integrin/FAK signaling that is therapeutically reversible by a probiotic bacteriocin
Kamarajan, P., Ateia, I., Shin, J. M., Fenno, J. C., Le, C., Zhan, L., Chang, A., Darveau, R., & Kapila, Y. L. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008881 · Cited by 134
Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives
Ahmed, S., Khan, H. Z., Fratantonio, D., Hasan, M. M., Sharifi, S., Fathi, N., Ullah, H., & Rastrelli, L. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152883 · Cited by 134
Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix
Mekhdjian, A. H., Kai, F., Rubashkin, M. G., Prahl, L. S., Przybyla, L., McGregor, A., Bell, E. S., Barnes, J. M., DuFort, C. C., Ou, G., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-09-0654 · Cited by 140
Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
Siu, M. K. Y., Jiang, Y., Wang, J., Leung, T., Han, C. Y., Tsang, B. K., Cheung, A., Ngan, H., & Chan, K. K. L. (2019) · Cancers · doi:10.3390/cancers11060813 · Cited by 135
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut · doi:10.1136/gutjnl-2018-317424 · Cited by 130
Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
Mashreghi, M., Azarpara, H., Bazaz, M. R., Jafari, A., Masoudifar, A., Mirzaei, H., & Jaafari, M. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26049 · Cited by 129
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 136
Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
Chan, K. K. L., Siu, M. K. Y., Jiang, Y., Wang, J., Leung, T. H. Y., & Ngan, H. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0559-2 · Cited by 126
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis
Geng, Y., Liu, X., Liang, J., Habiel, D. M., Kulur, V., Coelho, A. L., Deng, N., Xie, T., Wang, Y., Liu, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125326 · Cited by 127
CXCL8 in Tumor Biology and Its Implications for Clinical Translation
Xiong, X., Liao, X., Qiu, S., Xu, H., Zhang, S., Wang, S., Ai, J., & Yang, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.723846 · Cited by 129
An Experimenter’s Guide to Glioblastoma Invasion Pathways
de Gooijer, M. C., Navarro, M. G., Bernards, R., Würdinger, T., & van Tellingen, O. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.07.003 · Cited by 129
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Law, R. P., Nunes, J., Chung, C., Bantscheff, M., Buda, K., Dai, H., Evans, J. P., Flinders, A., Klimaszewska, D., Lewis, A. J., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109237 · Cited by 122
Targeting of proangiogenic signalling pathways in chronic inflammation
Tas, S. W., Maracle, C. X., Balogh, E., & Szekanecz, Z. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.164 · Cited by 123
Glioblastoma: Current Status, Emerging Targets, and Recent Advances
Thakur, A., Faujdar, C., Sharma, R., Sharma, S., Malik, B., Nepali, K., & Liou, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01946 · Cited by 122
Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment
Riggi, N., Aguet, M., & Stamenkovic, I. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-044127 · Cited by 121
FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β
Gao, C., Chen, G., Kuan, S., Zhang, D. H., Schlaepfer, D. D., & Hu, J. (2015) · eLife · doi:10.7554/elife.10072 · Cited by 118
Self-citation
Extracellular Matrix Components and Mechanosensing Pathways in Health and Disease
Berdiaki, A., Neagu, M. T., Tzanakakis, P., Spyridaki, I., Pérez, S., & Nikitovic, D. (2024) · Biomolecules · doi:10.3390/biom14091186 · Cited by 117
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation
Song, X., Xu, H., Wang, P., Wang, J., Affò, S., Wang, H., Xu, M. M., Liang, B.-Y., Che, L., Qiu, W., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.018 · Cited by 117
Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
Lander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0192 · Cited by 114
FAK and paxillin, two potential targets in pancreatic cancer
Kanteti, R., Batra, S. K., Lennon, F. E., & Salgia, R. (2016) · Oncotarget · doi:10.18632/oncotarget.8040 · Cited by 121
Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment
Li, Z., Zheng, Z., Wei, Z.-H., Zhang, L., Li, F., Lin, L., Liu, R., Huang, X., Lv, J., Chen, F., et al. (2019) · Theranostics · doi:10.7150/thno.36585 · Cited by 114
Feeling Things Out: Bidirectional Signaling of the Cell–ECM Interface, Implications in the Mechanobiology of Cell Spreading, Migration, Proliferation, and Differentiation
Miller, A. E., Hu, P., & Barker, T. H. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901445 · Cited by 119
Reciprocal Interplay Between Fibrillar Collagens and Collagen‐Binding Integrins: Implications in Cancer Progression and Metastasis
Bourgot, I., Primac, I., Louis, T., Noël, A., & Maquoi, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01488 · Cited by 113
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma
Balsas, P., Palomero, J., Eguileor, Á., Rodríguez, M. L., Vegliante, M. C., Planas‐Rigol, E., Sureda-Gómez, M., Cid, M. C., Campo, E., & Amador, V. (2017) · Blood · doi:10.1182/blood-2017-04-776740 · Cited by 112

Authors: Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D.
Affiliations: University of California San Diego (US)
Corresponding author: Schlaepfer, David D.
ORCID: Sulzmaier, Florian J.
Jean, Christine
Schlaepfer, David D.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-08-07
Volume: 14
Issue: 9
Pages: 598-610
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3792
PMC: PMC4365862
OpenAlex: W2044423100
Cited by: 1,381
References: 142
Citations by year: 2026: 92 · 2025: 85 · 2024: 131 · 2023: 111 · 2022: 147 · 2021: 154 · 2020: 144 · 2019: 122 · 2018: 105 · 2017: 128 · 2016: 91 · 2015: 63 · 2014: 6
FWCI: 12.73
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HAL (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: American Heart Association
Verastem Oncology
National Institutes of Health
National Cancer Institute (R01CA102310, CA102310, R01CA180769, CA180769, T32CA121938)
Topics: Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: focal adhesion kinase, FAK inhibitors, tumor microenvironment, tumor stromal cells, metastasis, tumor progression, cancer stem cells, cell invasion, cell migration, small molecule inhibitors, clinical development
MeSH terms: Animals, Humans, Neoplasm Invasiveness, Neoplasms, Signal Transduction, Stromal Cells, Protein Kinase Inhibitors, Focal Adhesion Kinase 1, Small Molecule Libraries, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FAK in cancer: mechanistic findings and clinical applications

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks